Key Points
- John Gill, a director of Altimmune, bought 12,500 shares on Dec. 23 at an average price of $4.10 per share (total ~$51,250), a transaction disclosed in an SEC Form 4 filing.
- The purchase follows another recent director buy (Jerome Benedict Durso bought 12,500 shares at $4.13 on Dec. 22), with these insider buys collectively signaling increased insider conviction in the company’s near‑term prospects.
- Pemvidutide 48‑week data showed durable, dose‑dependent antifibrotic signals, consistent safety, and meaningful weight loss (up to ~7.5%), positioning Altimmune to advance a biopsy‑based Phase III and potentially de‑risking the stock’s outlook.
Altimmune, Inc. (NASDAQ:ALT - Get Free Report) Director John Gill purchased 12,500 shares of Altimmune stock in a transaction dated Tuesday, December 23rd. The stock was acquired at an average cost of $4.10 per share, with a total value of $51,250.00. Following the completion of the acquisition, the director directly owned 12,500 shares in the company, valued at approximately $51,250. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Altimmune Trading Down 3.4%
NASDAQ:ALT opened at $4.00 on Wednesday. The company has a debt-to-equity ratio of 0.08, a quick ratio of 17.18 and a current ratio of 17.18. Altimmune, Inc. has a 1 year low of $2.90 and a 1 year high of $8.05. The stock has a fifty day moving average price of $4.52 and a two-hundred day moving average price of $4.38. The stock has a market capitalization of $417.36 million, a price-to-earnings ratio of -3.74 and a beta of -0.03.
Altimmune (NASDAQ:ALT - Get Free Report) last issued its earnings results on Thursday, November 6th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.29) by $0.08. Altimmune had a negative net margin of 419,575.00% and a negative return on equity of 54.79%. The company had revenue of $0.01 million during the quarter, compared to analysts' expectations of $0.00 million. As a group, sell-side analysts anticipate that Altimmune, Inc. will post -1.35 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Altimmune
Large investors have recently added to or reduced their stakes in the company. Victory Capital Management Inc. acquired a new stake in shares of Altimmune during the third quarter valued at about $38,000. BNP Paribas Financial Markets lifted its holdings in Altimmune by 108.5% during the 2nd quarter. BNP Paribas Financial Markets now owns 10,095 shares of the company's stock worth $39,000 after buying an additional 5,253 shares during the last quarter. Kingswood Wealth Advisors LLC acquired a new position in shares of Altimmune in the 2nd quarter worth approximately $40,000. Prudential Financial Inc. acquired a new position in Altimmune in the second quarter worth $43,000. Finally, Sequoia Financial Advisors LLC acquired a new stake in shares of Altimmune during the third quarter worth $46,000. 78.05% of the stock is owned by institutional investors and hedge funds.
More Altimmune News
Here are the key news stories impacting Altimmune this week:
- Positive Sentiment: Pemvidutide 48‑week IMPACT data showed durable, dose‑dependent antifibrotic signals, consistent safety, and meaningful weight loss (up to ~7.5% at 1.8 mg); Altimmune is positioned to advance a biopsy‑based Phase III (planned higher dose) and appears to have constructive regulatory alignment — a key clinical de‑risking step that can materially improve the stock’s outlook. Read More.
- Positive Sentiment: Director Jerome Benedict Durso bought 12,500 shares at an average $4.13 on Dec 22, signaling insider conviction and increasing insider ownership. SEC filing: Read More.
- Positive Sentiment: Director John Gill purchased 12,500 shares at an average $4.10 on Dec 23, another independent insider buy that reinforces management confidence in near‑term clinical and corporate prospects. SEC filing: Read More.
- Neutral Sentiment: On balance, sell‑side coverage remains mixed but constructive: the stock has an average analyst recommendation of “Moderate Buy,” which provides some institutional support but reflects varying views on commercialization and pricing risks. Read More.
- Negative Sentiment: Some sell ratings and cautious notes remain in the market (e.g., a reiterated Weiss Ratings “sell (d‑)”), underscoring the continued risk that clinical/regulatory or commercial execution could disappoint—factors that can cap near‑term upside despite positive data. Read More.
Wall Street Analyst Weigh In
Several analysts have commented on ALT shares. Citizens Jmp lowered their target price on shares of Altimmune from $15.00 to $14.00 and set a "market outperform" rating for the company in a research note on Friday, November 7th. Weiss Ratings restated a "sell (d-)" rating on shares of Altimmune in a report on Monday. HC Wainwright reiterated a "buy" rating and set a $12.00 price objective on shares of Altimmune in a report on Monday, October 20th. Finally, Citigroup reaffirmed a "market outperform" rating on shares of Altimmune in a research note on Wednesday, November 12th. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $16.83.
Get Our Latest Stock Report on ALT
About Altimmune
(
Get Free Report)
Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune's approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.
Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
